Key Takeaways
- Sector Rally: Caris Life Sciences (CAI) stock jumped 9.61% to close at $31 on Thursday, September 17, riding a Fed-driven market rally and a surge across AI-powered precision oncology peers.
- Target Flip: The Street’s mean target of $28 now sits 11% below CAI stock’s close, the first time in over a year the price has run ahead of it.
- Coverage Split: The 14 analysts TIKR tracks on CAI stock carry 9 buys, 1 outperform and 4 holds, with holds climbing every quarter since December.
- Model Gap: TIKR’s mid-case model puts CAI stock’s fair value at $119 by December 2030, implying a 285% total return and a 37% annualized rate.
See why the Street’s $28 target trails Caris Life Sciences stock, and analyze CAI stock on TIKR for free →
Why Caris Life Sciences Stock Jumped 10% Alongside Diagnostics Peers
Caris Life Sciences (CAI) stock jumped 10% to close at $31 on Thursday, September 17, as a market-wide rally following the Federal Reserve’s rate hike pulled growth names higher and lifted its closest genomic profiling peers even further. The Nasdaq climbed 1.69% that day as Treasury yields retreated from the prior session’s selloff, and technology stocks led the broader market with a 2.25% gain.
The move wasn’t isolated to Caris. Tempus AI (TEM), the AI-driven diagnostics company that competes directly for oncology testing volume, climbed roughly 14% the same day after Morgan Stanley flagged up to $400 million in previously uncounted reimbursement revenue tied to its xT and xF tests. Moderna added another 9% on separate cancer vaccine data. A market recap that day specifically called out continued strength across AI-enabled precision medicine names, and Caris sits in that same category.
Insiders didn’t wait to see if the rally held. Vice Chairman Brian Brille exercised options and sold 400,000 shares that same day for $12.1 million, cutting his direct stake by more than 63%.
No filing, earnings update or analyst note tied specifically to Caris landed on September 17. The stock moved with its group, not ahead of it, and that gap between a sector-wide repricing and company-specific news is what the rest of this article has to weigh.
Track how Tempus AI’s Thursday surge rippled into Caris Life Sciences stock, and compare CAI stock on TIKR for free →
Caris Life Sciences Stock’s Rally Outpaces a Street Target Stuck Near $28
The 14 analysts TIKR tracks on CAI stock carry 9 buys, 1 outperform and 4 holds, with no underperform or sell rating anywhere in the mix. Their mean target of $28 now sits 11% below Thursday’s $31 close, the first time in this dataset the average target has trailed the price instead of leading it.
That gap is new. The mean target fell every quarter over the past year, from $39 in September 2025 to $38 in December, $33 in March and $28 by June, even as the stock swung the other way, cratering from $30 to $18 before rallying back above $31 by September. Coverage grew alongside the cuts, from 8 price-target estimates a year ago to 13 now, and holds climbed from zero to 4 as some analysts turned more cautious into the rebound. Add it up and the Street never caught back up to Thursday’s move.
TIKR Values CAI Stock at $119, Pricing In Years of Growth Ahead
TIKR’s mid-case model values Caris Life Sciences at $119 by December 2030, implying a 285% total return from the current price of $31, or 37% annualized over 4.3 years.
A 37% annualized return stacked on top of Thursday’s double-digit pop puts CAI stock well outside the return profile investors expect from an established diagnostics name and closer to what a still-scaling growth story has to deliver to justify the price.
The target rests on Caris sustaining the pace behind its record second quarter, total revenue up 45% year over year, molecular profiling revenue up 55%, gross margin at 68% and clinical case volume up 18%, output the Street’s own $28 mean target hasn’t caught up to. Thursday’s rally closed part of that gap on sentiment alone, with no company-specific news behind it, which is exactly why the model and the Street now point in different directions on CAI stock.
Street’s consensus estimate puts Caris Life Sciences’ third-quarter revenue at $256 million, up 18% year over year, a sharp deceleration from the 45% growth posted in the second quarter and a sequential dip from that quarter’s $264 million. That slowdown was already in the Street’s numbers before Thursday’s rally, and it widens the gap between the near-term consensus and the growth rate embedded in consensus’ $119 target.
See how a $119 target and a 285% return stack up for CAI stock, and check it on TIKR for free →
Should You Invest in Caris Life Sciences, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CAI stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Caris Life Sciences, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze CAI stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
